Reviparin

DB09259ApprovedSmall molecule

Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin. It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin... It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.

Mechanism
Curator reviewed
Primary indication
By the FDA, reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients.Curator reviewed · 2 structured indications
Also known as
Reviparin sodium

Resolves to

Compound
UNII5R0L1D739ECAS9041-08-1KEGGD03337
Clinical / RWD
RxNorm75960ATCB01AB08
Targets
P00734F2P00742F10P01008SERPINC1P02751FN1

What you can answer from here — as of July 03, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
865Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
24Marketed productsAcross 2 countries and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in
11+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Reviparin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In